HFCWO in Hospitalized Asthmatic Children
High Frequency Chest Wall Oscillation in Hospital Management of Asthmatic Children
1 other identifier
interventional
43
1 country
2
Brief Summary
To determine whether or not high frequency chest wall oscillation (in the form of the VestTM) is superior to regular asthma therapy in the management of children hospitalized with moderate to severe asthma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2008
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedFirst Submitted
Initial submission to the registry
July 23, 2008
CompletedFirst Posted
Study publicly available on registry
July 25, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2010
CompletedResults Posted
Study results publicly available
November 24, 2015
CompletedAugust 7, 2017
July 1, 2017
1.9 years
July 23, 2008
August 25, 2015
July 7, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Primary Endpoint Will be Time to Readiness for Discharge.
Days in the hospital prior to patient being clinically ready to discharge
30 days
Secondary Outcomes (1)
Secondary Endpoint Total Hospital Length of Stay
30 Days
Study Arms (2)
Vest Arm
EXPERIMENTALHFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
Control
NO INTERVENTIONHistorical control for PICU asthma patients
Interventions
Eligibility Criteria
You may qualify if:
- Any pediatric patient between the ages of 18 months and 18 years admitted to Winthrop University Hospital's pediatric floor or intensive care unit with a diagnosis of asthma or reactive airway disease
You may not qualify if:
- Patients with chronic, comorbid respiratory conditions (e.g., cerebral palsy, cystic fibrosis)
- Those who regularly use HFCWO
- Any patient exhibiting an absolute contraindication to HFCWO therapy
- Absolute contraindications to using HFCWO include head and neck injury prior to stabilization, and active hemorrhage with hemodynamic instability
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hill-Romlead
Study Sites (2)
Winthrop University Hospital, Winthrop Pediatric Associates
Long Island City, New York, 11501, United States
Winthrop University Hospital
Long Island City, New York, 11501, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Jon Roberts, MD
- Organization
- Winthrop University
Study Officials
- PRINCIPAL INVESTIGATOR
Jon Roberts, MD
Winthrop University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 23, 2008
First Posted
July 25, 2008
Study Start
July 1, 2008
Primary Completion
June 1, 2010
Study Completion
July 1, 2010
Last Updated
August 7, 2017
Results First Posted
November 24, 2015
Record last verified: 2017-07